Skip to content
Research archive

Research Articles

Randomized Controlled Trial

Web-Based Personalized Machine Learning Recommendations to Enhance Shared Decision-Making in Prostate-Specific Antigen Screening: Randomized Controlled Trial.

ML-Driven PSA Screening Recommendations Reduce Decisional Conflict in Older Men — Men who received personalized machine learning–generated PSA screening recommendations reported meaningfully lower decisional conflict than controls, with a mean score difference of -3.

Apr 21, 2026 · JMIR Aging · Oncology
81
Clinical Trial

FDA Approval Summary: Durvalumab for the Treatment of Adult Patients with Muscle-Invasive Bladder Cancer.

Durvalumab Added to Perioperative Chemotherapy Improves Survival in Muscle-Invasive Bladder Cancer — In cisplatin-eligible adults with muscle-invasive bladder cancer, adding durvalumab to standard gemcitabine-cisplatin chemotherapy as both a neoadjuvant and adjuvant treatment reduced the risk of disease progression or death by approximately 32% compared with chemotherapy alone (EFS HR 0.

Apr 21, 2026 · Clin Cancer Res · Oncology
84
Clinical Trial

Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.

Relacorilant Plus Nab-Paclitaxel Significantly Extends Overall Survival in Platinum-Resistant Ovarian Cancer — Adding relacorilant to nab-paclitaxel reduced the risk of death by approximately 35% compared with nab-paclitaxel alone in patients with platinum-resistant ovarian cancer, extending median overall survival by 4.

Apr 21, 2026 · Lancet · Oncology
84
Randomized Controlled Trial

Certolizumab pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: 48-week patient-reported outcomes from the NORD-STAR trial.

Biological DMARDs Offer Modest Pain Gains Over Conventional Therapy in Early RA — At 48 weeks, all four treatment arms in the NORD-STAR trial produced large, clinically meaningful improvements in patient-reported outcomes, with certolizumab pegol and abatacept yielding pain relief exceeding the minimal clinically important difference in 76% and 79% of patients respectively, compared with 68% in the active conventional treatment group.

Apr 20, 2026 · Lancet Rheumatol · Immunology
80
Clinical Trial

Randomized Trial of Adjunctive Prednisolone for Kawasaki Disease.

Adjunctive Prednisolone Fails to Reduce Coronary-Artery Lesions in Kawasaki Disease — Adding prednisolone to standard treatment for Kawasaki disease did not reduce the incidence of coronary-artery lesions at one month after illness onset compared with standard treatment alone — 16.

Apr 20, 2026 · N Engl J Med · Cardiology
90
Randomized Controlled Trial

Systolic Blood Pressure Trajectory and Outcomes in Acute Intracerebral Hemorrhage: Pooled Analysis of the 4 INTERACT and ATACH-II Clinical Trials.

Sustained Hypertensive SBP Trajectory Carries Highest Risk of Poor Outcome After ICH — In a pooled analysis of 11,269 patients with acute intracerebral hemorrhage, those who maintained a persistently elevated systolic blood pressure trajectory over the first 24 hours had the greatest odds of death or disability at 90 days, regardless of which blood pressure-lowering strategy was applied.

Apr 19, 2026 · Neurology · Cardiology
80
Randomized Controlled Trial

Efficacy of front-of-package nutrient labels designed for mandatory implementation in the USA: an online randomised controlled trial.

Alternative Front-of-Package Labels Outperform FDA's Proposed Nutrition Scheme in US Adults — In a nationally representative randomised controlled trial of 13,929 US adults, a multilabel warning scheme highlighting only high-nutrient-content items (Multi-High-In) reduced selection of unhealthy foods by 5.

Apr 19, 2026 · Lancet Public Health
80
Research Article

Bedside model-informed precision dosing of vancomycin in severely ill neonates and children in Belgium (the BENEFICIAL trial): a multicentre, randomised controlled trial.

Bayesian Precision Dosing Significantly Improves Vancomycin Target Attainment in Critically Ill Children — In a multicentre randomised controlled trial, model-informed precision dosing (MIPD) of vancomycin achieved the pharmacokinetic/pharmacodynamic target in nearly 72% of critically ill children, compared with 54% under standard therapeutic drug monitoring — an absolute improvement of 18.

Apr 18, 2026 · Lancet Child Adolesc Health · Pediatrics
81